Fennec Pharmaceuticals to Release Second Quarter Financials
Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a recognized name in the specialty pharmaceutical sector, has announced its intention to release its second quarter financial results. This important update will occur before the opening of the U.S. financial markets on a Thursday. As the date approaches, expectations are high for what the company will reveal.
Key Information about the Financial Results
The scheduled release date for these financial results is significant for investors and stakeholders alike. On that Thursday morning, management will also conduct a conference call and a webcast to communicate financial performances and discuss vital business developments.
Details of the Conference Call
During the conference call that coincides with the financial results release, interested parties will have the chance to gain important insights directly from management. Here are the key details for the call:
Timing and Access
Date: Thursday
Time: 8:30 a.m. Eastern Time
How to Join
Those interested in attending can access the conference call via a webcast link, which will be available on the company website under the News & Events/Event Calendar page. It is recommended to connect at least 15 minutes in advance to allow ample time for any necessary software downloads. Furthermore, a recorded version of the conference will be maintained on the site for those unable to attend live.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals is committed to supporting cancer patients by addressing one of the often-overlooked consequences of treatment: ototoxicity, which can lead to significant hearing loss. The company’s cornerstone product, PEDMARK, is designed to mitigate the risks associated with cisplatin treatment, known for its potential ototoxic effects.
Regulatory Approvals and Market Presence
Having received FDA approval in 2022, alongside endorsements from European authorities in 2023, PEDMARK has solidified Fennec’s position in the market. Additionally, the product operates under the brand name PEDMARQSI in various international markets, including the United Kingdom and Germany.
Collaborative Efforts and Commercialization
Fennec recently entered a pivotal licensing agreement with Norgine Pharmaceuticals, aiming to broaden the distribution of PEDMARQSI across Europe, the U.K., Australia, and New Zealand. This collaboration is expected to enhance the company’s market presence significantly, driving further growth and accessibility for patients in need.
Protective Measures and Future Outlook
PEDMARK's recognition as an Orphan Drug in the U.S. underscores its unique position and the vital need it serves. Fennec’s proactive approach has extended its patent protection until 2039, ensuring that they can continue to innovate while protecting their intellectual property.
Company Vision and Commitment
As Fennec Pharmaceuticals moves forward, its commitment to providing life-altering solutions for patients dealing with the side effects of cancer treatment remains front and center. With innovative treatments and strategic partnerships, Fennec is poised to make a lasting impact in the specialty pharmaceutical arena.
Frequently Asked Questions
When will Fennec Pharmaceuticals release its financial results?
Fennec Pharmaceuticals is set to release its financial results on a Thursday before the U.S. market opens.
How can I access the conference call?
You can access the conference call via the company's website where the webcast link will also be provided.
What is PEDMARK?
PEDMARK is Fennec Pharmaceuticals' key product aimed at preventing chemotherapy-induced hearing loss.
Who will present during the conference call?
Management from Fennec Pharmaceuticals will present during the conference call to provide insights and updates.
What are the company's future plans?
Fennec Pharmaceuticals plans to expand its market presence and enhance access to its products through strategic partnerships.
